Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
February 22, 2026Clinical Cancer Research

Abstract PS2-09-24: Aurora Kinase A (AURKA) a new druggable target in ER+ Inflammatory Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

TSTushar SharmaANA. NasrazadaniWMWencai Ma

Discussion

Loading...

Member takes

Overview

Pilot studies demonstrate AURKA as a viable therapeutic target in ER+ inflammatory breast cancer, indicating potential for novel treatment strategies.

Key Points

  • This research aims to explore Aurora Kinase A (AURKA) as a therapeutic target in metastatic ER+ inflammatory breast cancer.
  • Reviewed RNA and DNA data from tumor assays in IBC and non-IBC cases.
  • Tested AURKA protein expression and efficacy of Alisertib in ER- IBC cell lines using crystal violet staining.
  • Examined senescence via B-gal and ELISA assays.
  • Established ER+ patient-derived organoids as an ER+ IBC model.
  • AURKA is amplified in 14 out of 21 ER+ IBC compared to 432 ER+ non-IBC samples, showing co-occurrence with synthetic lethal targets.
  • Significant inverse correlation found between AURKA and SMARCA4 specifically in IBC.
  • Higher AURKA doses induced reversible senescence in IBC cell lines, suggesting a mechanism for overcoming treatment resistance.

Cite This Study

Sharma et al. (2026) studied this question.

synapsesocial.com/papers/699a9dc0482488d673cd3e08https://doi.org/10.1158/1557-3265.sabcs25-ps2-09-24
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 452: Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer.2026
  2. 2Abstract 7126: Targeting Aurora A kinase together with alternative survival signaling overcomes resistance to endocrine and CDK4/6 therapies in ER+ breast cancer2026
  3. 3Abstract 708: Targeting aurora kinase B (AURKB) as a radiosensitizing strategy in syngeneic models of triple negative breast cancer (TNBC)2024 · 1 citations
  4. 4Abstract PS2-11-08: Stemness-targeted therapies to enhance the efficacy of AURKA inhibitors in endocrine resistant er+ breast cancer2026
  5. 5Abstract 6604: Aurora kinase B inhibition enhances radiation response and activates type 1 interferon signaling in triple-negative breast cancer.2026